Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseasePenile CarcinomaSubgroupICD10C60.-MeSHPenile NeoplasmsUrethral NeoplasmsSequenceCETU400, Penile Cancer, C1 (PID2745) -|- CETU250, C2+ (PID2746)HERCULES (LACOG 0218): PEMB200/CISP70/FU1000, Penile Cancer, C1-6 (PID3025) or PEMB200/CRBP5/FU1000, Penile Cancer, C1-6 (PID3026) -|- PEMB200, C7+ (PID3027)Antineoplastic therapySubstanceCarboplatinCetuximabCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelPembrolizumabVinfluninSubstanceCarboplatinCetuximabCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelPembrolizumabVinfluninSubstanceCarboplatinCetuximabCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelPembrolizumabVinfluninSubstanceCarboplatinCetuximabCisplatinDacomitinibDocetaxelFluorouracilIfosfamidePaclitaxelPembrolizumabVinfluninNo. Substances123 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineNaCl 0.9%PegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineNaCl 0.9%PegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineNaCl 0.9%PegfilgrastimPotassium chlorideSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineNaCl 0.9%PegfilgrastimPotassium chlorideNo. Substances134578910Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseMaintenanceneoadjuvantneoadjuvant / adjuvantTherapy intentioncurativepalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEdemaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHypercalcemiaHyperglycemiaHyperthyroidismHypothyroidismInfectionsMucositisMyalgiasNephrotoxicityNeuropathyNeutropeniaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorCarthon BCCotait Maluf FDi Lorenzo GHussein ANecchi ANicholson SNoronha VPagliaro LPizzocarro GDiseasePatienten mit primär nicht resektablen Lymphnotenmetastasen oder Rezidiv der LymphknotenmetastasenPenis-Ca, vortherapiert mit CisplatinPeniskarzinom, high-risk, adjuvantPeniskarzinom, lokal fortgeschritten, inoperabelPeniskarzinom, lokal fortgeschritten, inoperabel, mind. 1 VortherapiePeniskarzinom, metastasiert oder lokal fortgeschritten, ECOG 0-1Peniskarzinom, metastasiert oder lokal fortgeschritten, ECOG 0-2Peniskarzinom, TxN3M0 / T4NxM0, oder rezidiviert, inoperabel, Erstlinie, ECOG 0-1Peniskarzinom im Stadium cTx, cN2/N3, cM0, ECOG 0-2, neoadjuvante TherapieRezidiviertes oder nicht-resezierbares Penis-/UrethrakarzinomOriginDepartment of Genitourinary Medical Oncology, The University of Texas, Houston, TexasDepartment of Medical Oncology, Charing Cross Hospital, London, UKDepartment of Medical Oncology, Charing Cross Hospital, London, UK, CRUK/09/001 trialDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, IndiaFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Her-Uro-01 trialGenitourinary Cancer Section and Rare-Cancer Center, University Federico II, Naples, ItalyGenitourinary Oncology and Rare Cancer Center, Federico II University, Naples, ItalyLatin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil, HERCULES (LACOG 0218) TrialSylvester Comprehensive Cancer Center, University of Miami School of Medicine, FloridaThe University of Texas MD Anderson Cancer Center, Houston, USAUrologic Clinic 2nd, S. Giuseppe Hospital, Milan University, Milan, ItalyProtocols in Revision 14 protocols foundCetuximab 250, Penile Carcinoma, Cycle 2+ (PID2746 V1.0)Cetuximab 400, Penile Carcinoma, Cycle 1 (PID2745 V1.0)Cisplatin 100 / Fluorouracil 960, Penile Carcinoma (PID1443 V1.2)Cisplatin 75 / Fluorouracil 900, Penile Carcinoma (PID2744 V1.0)Dacomitinib 45, Penile Carcinoma (PID2742 V1.0)Docetaxel 75 / Cisplatin 60 / Fluorouracil 750, Penile Carcinoma (PID2740 V1.0)Paclitaxel 120 / Cisplatin 50 / Fluorouracil 1000, Penile Carcinoma (PID1442 V1.2)Paclitaxel 175 / Cisplatin 75, Penile Carcinoma (PID2747 V1.0)Paclitaxel 175, Penile Carcinoma (PID1648 V1.0)Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Penile Carcinoma, Cycle 1-6 (PID3026 V1.0)Pembrolizumab 200 / Cisplatin 70 / Fluorouracil 1000, Penile Carcinoma, Cycle 1-6 (PID3025 V1.0)Pembrolizumab 200, Penile Carcinoma, cycle 7+ (PID3027 V1.0)TIP (Paclitaxel 175 / Ifosfamide 1.2 / Cisplatin 25), Penile Carcinoma, neoadjuvant / adjuvant. (PID1444 V1.1)Vinflunin 320, Penile Carcinoma (PID2741 V1.0)
